Form D · Biotechnology
Ceres Nanosciences, Inc.
Manassas, VA · CIK 0001697394
Offering snapshot reported Sep 9, 2022 · SEC filing
- Reported sold
- $5M Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $5M Reported outside-investor minimum
- First sale
- Sep 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 9, 2022 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Feb 7, 2017 | Initial | $2,999,998 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-458426
Source: Form D, filed Sep 9, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ross Dunlap | Director, Executive |
| Thomas Dunlap | Executive |
| Scott Gazelle | Director |
| Tom Miller | Director |
| Emanuel Petricoin | Director |
| Emanuel Petricoin Iii | Director |
| Ian Wright | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9460 Innovation Dr
Manassas, VA, 20110
Manassas, VA, 20110